However, some studies have shown that a significant proportion of patients with normal ALT also had steatohepatitis and fibrosis on liver biopsy[30-32], indicating that aminotransferase per se cannot be used as a surrogate marker to assess the significant potential in therapies in patients with NASH. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.